2. Academic Validation
  3. Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering

Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering

  • Bioorg Med Chem Lett. 2015 Dec 15;25(24):5743-7. doi: 10.1016/j.bmcl.2015.10.079.
Jeffrey W Johannes 1,  Lynsie Almeida 1,  Kevin Daly 1,  Andrew D Ferguson 1,  Shaun E Grosskurth 1,  Huiping Guan 1,  Tina Howard 2,  Stephanos Ioannidis 1,  Steven Kazmirski 1,  Michelle L Lamb 1,  Nicholas A Larsen 1,  Paul D Lyne 1,  Keith Mikule 1,  Claude Ogoe 1,  Bo Peng 1,  Philip Petteruti 1,  Jon A Read 3,  Nancy Su 1,  Mark Sylvester 1,  Scott Throner 1,  Wenxian Wang 1,  Xin Wang 1,  Jiaquan Wu 1,  Qing Ye 1,  Yan Yu 1,  Xiaolan Zheng 1,  David A Scott 1
Affiliations

Affiliations

  • 1 AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States.
  • 2 AstraZeneca R&D Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.
  • 3 AstraZeneca R&D Building 310, Milton Science Park, Cambridge CB4 0WG, United Kingdom.
PMID: 26546219 DOI: 10.1016/j.bmcl.2015.10.079
Abstract

The propensity for Cancer cells to accumulate additional centrosomes relative to normal cells could be exploited for therapeutic benefit in oncology. Following literature reports that suggested TNKS1 (tankyrase 1) and PARP16 may be involved with spindle structure and function and may play a role in suppressing multi-polar spindle formation in cells with supernumerary centrosomes, we initiated a phenotypic screen to look for small molecule poly (ADP-ribose) polymerase (PARP) Enzyme family inhibitors that could produce a multi-polar spindle phenotype via declustering of centrosomes. Screening of AstraZeneca's collection of phthalazinone PARP inhibitors in HeLa cells using high-content screening techniques identified several compounds that produced a multi-polar spindle phenotype at low nanomolar concentrations. Characterization of these compounds across a broad panel of PARP family Enzyme assays indicated that they had activity against several PARP family Enzymes, including PARP1, 2, 3, 5a, 5b, and 6. Further optimization of these initial hits for improved declustering potency, solubility, permeability, and oral bioavailability resulted in AZ0108, a PARP1, 2, 6 inhibitor that potently inhibits centrosome clustering and is suitable for in vivo efficacy and tolerability studies.

Keywords

Cell cycle; Centrosome; Oncology; PARP; Tankyrase.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100847
    PPAR抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z